Clinical trials: Oral Anticoagulants
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Prothrombin Complex Factor Deficiency
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists in patients with acquired deficiency of…
- Trial name
- NCT01159210
- Testing
- Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)
- Where
- 6 sites in Austria, Hungary
- Volunteers
- 61 people
- Sponsor
- Baxalta now part of Shire
Atrial Fibrillation
Non-vitamin K Oral Anticoagulants in Cardioversion
Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF).
- Trial name
- FinCV3 (NCT02911545)
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Surgery, Oral, Hemorrhage
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs. To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in…
- Conditions
- Surgery, Oral, Hemorrhage, Postoperative Complications, Oral Surgical Procedures
- Trial name
- NCT04662515
- Testing
- Type of surgery, Dabigatran, Rivaroxaban
- Where
- 2 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Malmö University
Venous Thromboembolism
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm…
- Trial name
- NCT02223260
- Testing
- dabigatran
- Where
- 4 sites in Canada, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Atrial Fibrillation
AIHEMAF - P "An Innovative Healthcare Model for AF Patients"
Non-profit observational study on the role of the community pharmacist and "the pharmacy of services" in the case management of patients suffering from atrial fibrillation and being treated with new generation oral anticoagulants
- Trial name
- AIHEMAF - P (NCT05086991)
- Testing
- Follow up
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Farmacia La Regina s.r.l.
Atrial Fibrillation
Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation
Use of new oral anticoagulants (NOAC) in patients before and after catheter based pulmonary vein isolation (PVI) is still controversial.
- Trial name
- NCT02569255
- Testing
- Pulmonary venous ostia isolation
- Volunteers
- 234 people
- Sponsor
- Private Hospital Heart Center Varde
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Safety Issues, Anticoagulant Toxicity
Clinical Pharmacist Anticoagulant Stewardship
Initiative to improve direct anticoagulant utilization involving programmatic review by clinical pharmacists in collaboration with multidisciplinary team.
- Trial name
- NCT03527615
- Testing
- Clinical Pharmacist Medication Review
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- Hadassah Medical Organization
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Maternal Complications After Oral Anticoagulation When Initiated Early and Late After Caesarean Section Done for Patients With Mechanical Heart Valve Prosthesis
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis
A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation .
- Trial name
- NCT04855110
- Testing
- Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant), Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Cairo University
Deep Venous Thrombosis
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
- Trial name
- NCT06913595
- Testing
- Direct Oral Anticoagulant., Low Molecular Weight Heparine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Atrial Fibrillation (AF), Ischemic Stroke
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
- Trial name
- SAFER-DOAC (NCT07713537)
- Testing
- DOAC Level
- Where
- 2 sites in Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Blood Transfusion, Hip Fracture Surgeries
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting…
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications
- Trial name
- OPTIMIZEDOAC (NCT07309848)
- Where
- 7 sites in Netherlands
- Volunteers
- 374 people
- Sponsor
- St. Antonius Hospital
Cerebrosinovenous Thrombosis
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard…
- Trial name
- NCT07523347
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- Muhammad Aamir Latif